Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Hosp Infect ; 108: 142-145, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33259880

RESUMO

BACKGROUND: SARS-CoV-2 is the virus responsible for the current global pandemic, COVID-19. Because this virus is novel, little is known about its sensitivity to disinfection. METHODS: We performed suspension tests against SARS-CoV-2 using three commercially available quaternary ammonium compound (Quat) disinfectants and one laboratory-made 0.2% benzalkonium chloride solution. FINDINGS: Three of the four formulations completely inactivated the virus within 15 s of contact, even in the presence of a soil load or when diluted in hard water. CONCLUSION: Quats rapidly inactivate SARS-CoV-2, making them potentially useful for controlling SARS-CoV-2 spread in hospitals and the community.


Assuntos
Compostos de Benzalcônio/farmacologia , COVID-19/prevenção & controle , Higienizadores de Mão/farmacologia , Compostos de Amônio Quaternário/farmacologia , SARS-CoV-2/efeitos dos fármacos , Anti-Infecciosos Locais/química , Anti-Infecciosos Locais/farmacologia , Compostos de Benzalcônio/química , COVID-19/diagnóstico , COVID-19/epidemiologia , COVID-19/virologia , Desinfetantes/química , Desinfetantes/classificação , Desinfetantes/farmacologia , Desinfecção/métodos , Higienizadores de Mão/química , Humanos , Compostos de Amônio Quaternário/química , SARS-CoV-2/genética , SARS-CoV-2/crescimento & desenvolvimento , Resultado do Tratamento
2.
Mol Ther ; 12(6): 1111-9, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16122987

RESUMO

Previous gene transfer studies of the herpes simplex virus type 1 (HSV-1) using the latency-associated transcript (LAT) promoter have reported a decrease in transgene expression in the brain over time, but the extent of this decrease has not been measured and it is unknown if expression eventually stabilizes. We examined LAT promoter-mediated transgene expression in the mouse brain for 1 year following intracranial injection with a HSV-1 vector expressing human beta-glucuronidase (GUSB). The vector genome copy number remained stable from 2 to 52 weeks. Quantitative reverse transcriptase PCR detected a peak of LAT intron expression at 2 weeks (corresponding to the end of the acute phase of viral infection), followed by stable expression during latency (13-52 weeks). The number of GUSB-positive cells also had a peak in the acute phase and then was stable during latency (13-52 weeks). GUSB enzymatic activity was maintained at 11% of normal at 6 and 12 months, indicating that the LAT promoter is capable of driving stable transgene expression in the brain.


Assuntos
Terapia Genética/métodos , Vetores Genéticos , Regiões Promotoras Genéticas , Simplexvirus/genética , Transgenes , Animais , Encéfalo/metabolismo , Chlorocebus aethiops , DNA/metabolismo , DNA Complementar/metabolismo , Genes Reporter , Genoma , Glucuronidase/metabolismo , Humanos , Hibridização In Situ , Íntrons , Camundongos , Plasmídeos/metabolismo , RNA Mensageiro/metabolismo , Proteínas Recombinantes/química , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Tempo , Células Vero
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...